{
  "id": 8024533,
  "title": "PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill",
  "url": "https://urgent.news/2026/09/17/pharmala-biotech-provides-corporate-update-change-of-auditor",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-17T12:32:43.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/pharmala-biotech-provides-corporate-update-change-of-auditor-retention-of-watertower-research-and-oak-hill"
  },
  "original_language": "en",
  "account": null,
  "summary": "TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today announced three corporate updates. 1. Change of Auditor: The Company determined that it was in its […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}